The role of TCZ in addressing the interleukin-6-mediated inflammatory pathways has been well-established in the field of rheumatological diseases, including rheumatoid arthritis, juvenile idiopathic arthritis (JIA), giant cell arteritis or cytokine release syndrome [7, 8]. The gene discussed is IL6; the disease is juvenile idiopathic arthritis.